Jingshi (Hangzhou) Pharmaceutical Co., Ltd.

Primary Objective: To investigate the pharmacokinetics of a single oral dose of the test formulation, tetraenemannaquinone soft capsules (15 mg, manufactured by Zhejiang Shapuaisi Pharmaceutical Co., Ltd.), and the reference formulation, tetraenemannaquinone soft capsules (trade name: Gulikang®, 15 mg, manufactured by Shibakawa Plant of Fuji Capsule Co., Ltd.), in healthy adult participants under fasting and postprandial conditions, and to evaluate the bioequivalence of the two formulations under fasting and postprandial administration. Secondary Objective: To evaluate the safety of a single oral dose of the test formulation (T) tetraenemannaquinone soft capsules and the reference formulation (R) tetraenemannaquinone soft capsules (Gulikang®) in healthy participants under fasting and postprandial conditions.

Primary objective: To study the pharmacokinetic behavior of a single application of the test formulation of 15g of levocaine cream (Specification: 1g: 25mg lidocaine, 25mg prilocaine; provided by Jingshi (Hangzhou) Pharmaceutical Co., Ltd.) and the reference formulation of 15g of levocaine cream (Specification: 1g: 25mg lidocaine, 25mg prilocaine; licensee: Aspen Pharma Trading Limited, provided by Jingshi (Hangzhou) Pharmaceutical Co., Ltd.) in healthy Chinese subjects, and to evaluate the bioequivalence of the two formulations applied on an empty stomach. Secondary objective: To evaluate the safety of a single application of the test formulation of levocaine cream and the reference formulation of levocaine cream in healthy Chinese subjects.

Main purpose: To evaluate the relative bioavailability and bioequivalence of dapoxetine hydrochloride tablets produced by Jingshi (Hangzhou) Pharmaceutical Co., Ltd. as the test preparation and dapoxetine hydrochloride tablets certified by Berlin-Chemie AG as the reference preparation.